Navigation Links
NuVasive Prices $200 Million Convertible Senior Notes Due 2013
Date:3/4/2008

SAN DIEGO, March 4 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced the pricing of $200 million principal amount of 2.25% Convertible Senior Notes due 2013 through an offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. NuVasive has also granted the initial purchasers an option to purchase up to $30 million of additional notes solely to cover over-allotments. The offering is scheduled to close on March 7, 2008, subject to satisfaction of customary closing conditions.

The notes will pay interest semiannually at a rate of 2.25% per annum. The notes will be convertible into shares of NuVasive common stock at a conversion rate of 22.3515 shares of common stock per $1,000 principal amount of notes, which is equal to a conversion price of approximately $44.74 per share.

NuVasive estimates that the net proceeds from the offering will be approximately $193.4 million after deducting the initial purchasers' discounts and commissions and estimated offering expenses, assuming no exercise of the initial purchasers' over-allotment option.

NuVasive intends to use the net proceeds from the offering for general corporate purposes, including potential strategic acquisitions. NuVasive has entered into convertible note hedge transactions with the initial purchasers or their affiliates (the "counterparties") and intends to use a portion of the net proceeds from this offering to pay for the cost of the convertible note hedge transactions. The convertible note hedge transactions are intended to reduce dilution experienced by the company's stockholders upon potential future conversion of the notes. The company has also entered into separate warrant transactions with the counterparties, which would result in additional proceeds to the company, and would partially offset the cost of the convertible note hedge transactions. The company estimates that the cost of the convertible note hedge transactions, taking into account the proceeds from the sale of the warrants, will be approximately $12.2 million. If the initial purchasers exercise their over-allotment option, the company will enter into additional convertible note hedge and warrant transactions.

In connection with establishing their initial hedge of these transactions, the counterparties and/or their respective affiliates expect to enter into various derivative transactions with respect to the company's common stock and may purchase shares of its common stock concurrently with, or shortly after, the pricing of the notes. These activities could have the effect of increasing, or preventing a decline in, the price of the common stock concurrently with or following the pricing of the notes.

In addition, the counterparties and/or their respective affiliates may modify their hedge positions by entering into or unwinding various derivative transactions with respect to the common stock or by selling or purchasing the common stock in secondary market transactions following the pricing of the notes and are likely to do so following any conversion of the notes and during the 84 scheduled trading day period prior to the maturity date, which could adversely affect the price of the common stock and of the notes or could have the effect of increasing or preventing a decline in the price of the common stock.

This announcement is neither an offer to sell nor a solicitation to buy any of the securities described herein and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful. The notes and the common stock issuable upon conversion of the notes have not been registered under the Securities Act of 1933, as amended, or any state securities laws, and are being offered in the United States only to qualified institutional buyers in reliance on rule 144A under the Securities Act. Unless so registered, the notes and common stock issuable upon conversion of the notes may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act and applicable state securities laws.

NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. There can be no assurance that the transactions contemplated in this announcement will be completed. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

Contact:

Kevin C. O'Boyle

EVP & Chief Financial Officer

NuVasive, Inc.

858-909-1800

investorrelations@nuvasive.com


'/>"/>
SOURCE NuVasive, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. NuVasive to Present at ThinkEquity Partners 5th Annual Growth Conference
2. NuVasive Announces Web Cast and Conference Call of Third Quarter 2007 Results
3. NuVasive Licenses Its Insert and Rotate Technology
4. NuVasive Cancels 10/24/07 Investor Reception Due to Concerns Over Southern California Fires
5. NuVasive to Present at BIOCOM Investor Conference 2007
6. NuVasive Announces Preliminary Unaudited Full Year 2007 Financial Results
7. NuVasive to Offer $200 Million Convertible Senior Notes Due 2013
8. Lincare Holdings Inc. Prices $500 Million Convertible Senior Debentures Offering
9. American Association for Homecare Disputes Validity of Internet Power Wheelchair Prices as Basis for Reimbursement of Services in Medicare
10. Mylan Prices Offerings of Common Stock and Mandatory Convertible Preferred Stock
11. Health care opinion leaders support public reporting of health care quality, prices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... Woodland Hills, CA (PRWEB) , ... December 09, ... ... center for young adults, celebrated its 10th anniversary with the grand opening of ... Hills, California. The successful event spanned two days, December 2-3, and was attended ...
(Date:12/9/2016)... NJ (PRWEB) , ... December 09, 2016 , ... ... Founders Ball at The Pierre Hotel in New York, NY, on December 3rd, ... benefactors, dignitaries and physicians attended the annual event, which raised over $1 million ...
(Date:12/9/2016)... ... December 09, 2016 , ... The Pennsylvania Athletic ... (PCN) during the summer of 2016. The program was made possible by a ... States Department of Health and Human Services Administration. The broadcast, Use Your ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Research Institute (WCRI) officially opened registration today for its 33rd Annual Issues ... Boston, MA . , The theme of the conference is “Persistent Challenges and ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Chester County, a Property owned by an affiliate of Seavest, has won a ... Penn Medicine Southern Chester County ambulatory care center (ACC) was named “Best New ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016 Australia Glaucoma ... GlobalData,s new report, "Australia Glaucoma Surgery Devices ... on the Australia Glaucoma Surgery Devices market. The ... volume (in units) and average prices (USD) within ... report also provides company shares and distribution shares ...
(Date:12/8/2016)... , Dec. 8, 2016 KEY FINDINGS ... poised to grow in 2017-2023. Various reasons for growth ... obese population, higher incidences of chronic diseases, high recovery ... mobility aid services. Medical lifting sling refers to ... with limited mobility. These slings connect to the lift ...
(Date:12/8/2016)... INDIANAPOLIS , Dec. 8, 2016  Eli Lilly ... detailed results of its phase 3 EXPEDITION3 trial at ... (CTAD) meeting. As previously disclosed, solanezumab did not meet ... study of solanezumab initiated in people with mild dementia ... pursue regulatory submissions for solanezumab for the treatment of ...
Breaking Medicine Technology: